Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merus N.V. - Common Shares (NQ: MRUS )

47.58 +0.83 (+1.78%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merus N.V. - Common Shares

< Previous 1 2 3 4 5 6 Next >
Why Glory Star New Media Group Shares Are Trading Higher By 122%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Glory Star New Media Group Holdings Limited (NASDAQ: GSMG) shares jumped 122% to $1.07 after the company announced the signing of a $60 million strategic investment with two institutional... 
Via Benzinga
Ericsson, Johnson & Johnson, Goldman Sachs And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping over 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
The Latest Analyst Ratings for Merus
Via Benzinga
4 Analysts Have This to Say About Merus
Via Benzinga
Merus Earnings Perspective: Return On Capital Employed
Via Benzinga
5 Analysts Have This to Say About Merus
Via Benzinga
What 4 Analyst Ratings Have To Say About Merus
Within the last quarter, Merus (NASDAQ:MRUS) has observed the following analyst ratings: 
Via Benzinga
Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)
From Merus N.V.
Via GlobeNewswire
Merus' Petosemtamab Abstract Hits Upside Scenario For Overall Response Rate, Duration Of Response: Analyst
Via Benzinga
Merus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR Annual Meeting 2023
From Merus N.V.
Via GlobeNewswire
Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 and Provides a Program and Regulatory Update
From Merus N.V.
Via GlobeNewswire
4 Analysts Have This to Say About Merus
Within the last quarter, Merus (NASDAQ:MRUS) has observed the following analyst ratings: 
Via Benzinga
What To Expect When Merus Presents Petosemtamab Data Update At AACR
Via Benzinga
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2023
Poster presentation: Tuesday, April 18, 2023, 1:30-5:30 p.m. ET 
From Merus N.V.
Via GlobeNewswire
Merus Announces Petosemtamab in Previously Treated Head and Neck Squamous Cell Carcinoma Abstract Selected for Plenary Session Oral Presentation at the AACR Annual Meeting 2023
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
MGM Resorts, Madison Square Garden Entertainment, Cardiovascular Systems And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Why Tivic Health Systems Are Trading Lower By 55%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Hempacco Co., Inc. (NASDAQ: HPCO) rose 296% to $2.99 after declining 6% on Wednesday. 
Via Benzinga
Merus to Participate in Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
CORRECTING and REPLACING --Merus Provides 2023 Outlook
From Merus N.V.
Via GlobeNewswire
Merus Provides 2023 Outlook
From Merus N.V.
Via GlobeNewswire
Merus to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the Third Quarter and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) shares jumped 242.8% to close at $105.72 on Thursday. The company announced a strategic plan to enter into the clean energy industry. 
Via Benzinga
Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Session
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) gained 64% to $50.60. 
Via Benzinga
Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
From Merus N.V.
Via GlobeNewswire
Why New Oriental Education Shares Jumped Over 28%; Here Are 68 Biggest Movers From Yesterday
Gainers ESSA Pharma Inc. (NASDAQ: EPIX) shares climbed 180.2% to close at $4.82 on Wednesday after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the... 
Via Benzinga
Why Seagate Shares Are Trading Lower By More Than 7%? Here Are 49 Stocks Moving In Wednesday's Mid-Day Session
Gainers ESSA Pharma Inc. (NASDAQ: EPIX) shares surged 59.3% to $2.7417 after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the 29th Annual Prostate... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.